[1] |
Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma[J].Nature,2014,513(7517):202-209.
|
[2] |
Kitajima K,Nakajo M,Kaida H,et al.Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update[J].Nagoya J Med Sci,2017 79(4): 527-543.
|
[3] |
Bar-Shalom R,Yefremov N,Guralnik L,et al.Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management[J].J Nucl Med,2003,44(8):1200-1209.
|
[4] |
Ajani JA,D'Amico TA,Almhanna K,et al.Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2016 ,14(10):1286-1312.
|
[5] |
Waddell T,Verheij M,Allum W,et al.Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol,2013,24 (Suppl 6):vi57-63.
|
[6] |
Wu CX,Zhu ZH.Diagnosis and evaluation of gastric cancer by positron emission tomography[J].World J Gastroenterol,2014,20(16):4574-4585.
|
[7] |
Chen W.Clinical applications of PET in brain tumors[J].J Nucl Med,2007 ,48(9):1468-1481.
|
[8] |
Kato T, hinoda J,Nakayama N,et al.Metabolic assessment of gliomas using 11C-methionine, 18Ffluorodeoxyglucose, and 11C-choline positron-emission tomography[J].AJNR Am J Neuroradiol,2008,29(6):1176-1182.
|
[9] |
Singhal T,Narayanan TK,Jacobs MP,et al.1C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI[J].J Nucl Med,2012,53(11):1709-1715.
|
[10] |
Zhang Y,Hong H,Cai W.PET tracers based on Zirconium-89[J].Curr Radiopharm,2011,4(2):131-139.
|
[11] |
Kim JC,Roh SA,Koo KH,et al.Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery[J].Int J Cancer,2002,97(4):542-547.
|
[12] |
Mery CM,Shafi BM,Binyamin G.Molecular imaging and radioimmunoguided surgery[J].Semin Pediatr Surg,2006,15(4):259-266.
|
[13] |
Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011 ,61(2):69-90.
|
[14] |
Nadauld LD,Ford JM.Molecular profiling of gastric cancer: toward personalized cancer medicine[J].J Clin Oncol,2013,31(7):838-839.
|
[15] |
Lee HS,Cho SB,Lee HE,et al.Protein expression profiling and molecular classification of gastric cancer by the tissue array method[J].Clin Cancer Res,2007,13(14):4154-4163.
|
[16] |
Kim MA,Lee HS,Lee HE,et al.EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number[J].Histopathology,2008,52(6):738-746.
|
[17] |
Terashima M,Kitada K,Ochiai A,et al.Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer[J]. Clin Cancer Res,2012,18(21):5992-6000.
|
[18] |
Yang W,Raufi A,Klempner SJ.Targeted therapy for gastric cancer: molecular pathways and ongoing investigations[J].Biochim Biophys Acta,2014,1846(1):232-237.
|
[19] |
Roskoski R Jr.The ErbB/HER family of protein-tyrosine kinases and cancer[J]. Pharmacol Res,2014,79:34-74.
|
[20] |
Ciardiello F,Damiano V,Bianco R,et al.Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A[J].J Natl Cancer Inst,1996,88(23):1770-1776.
|
[21] |
Mendelsohn J, Baselga J.Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].J Clin Oncol,2003,21(14):2787-2799.
|
[22] |
Cai W,Chen K,He L,et al.Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody[J]. Eur J Nucl Med Mol Imaging,2007,34(6):850-858.
|
[23] |
Schechter NR,Wendt RE 3rd,Yang DJ,et al.Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck[J]. J Nucl Med, 2004,45(10):1683-1687.
|
[24] |
Razumienko EJ,Chen JC,Cai Z,et al.Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates[J].J Nucl Med, 2016,57(3):444-452.
|
[25] |
Song IH,Lee TS,Park YS,et al.Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model[J].J Nucl Med,2016,57(7):1105-1111.
|
[26] |
Friedman M,Orlova A,Johansson E,et al.Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule[J].J Mol Biol,2008,376(5):1388-1402.
|
[27] |
Tolmachev V,Friedman M,Sandstrom M,et al.Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry[J].J Nucl Med,2009,50(2):274-283.
|
[28] |
Garousi J,Andersson KG,Mitran B,et al.PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules[J]. Int J Oncol,2016,48(4):1325-1332.
|
[29] |
Summer D,Garousi J,Oroujeni M, et al.Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression[J].Mol Pharm,2018,15(1):175-185.
|
[30] |
Pegram MD,Pauletti G,Slamon DJ.HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Research and Treatment[J].1998, 52(1-3):65-77.
|
[31] |
Freudenberg JA,Wang Q,Katsumata M,et al.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies[J].Exp Mol Pathol,2009,87(1):1-11.
|
[32] |
Kim JW,Im SA,Kim M,et al.The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen[J]. Anticancer Res,2012;32(4):1547-1553.
|
[33] |
Kim MA,Lee HS,Lee HE,et al.EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology[J]. 2008,52(6):738-746.
|
[34] |
Terashima M,Kitada K,Ochiai A,et al.Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer[J]. Clin Cancer Res,2012,18(21):5992-6000.
|
[35] |
Kleer CG,van Golen KL,Braun T,et al.Persistent E-cadherin expression in inflammatory breast cancer[J].Mod Pathol,2001,14(5):458-464.
|
[36] |
Stumpp MT,Amstutz P.DARPins: a true alternative to antibodies[J].Curr Opin Drug Discov Devel,2007,10(2):153-159.
|
[37] |
Zahnd C,Kawe M,Stumpp MT,et al.Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size[J].Cancer Res,2010,70(4):1595-1605.
|
[38] |
Jost C,Schilling J,Tamaskovic R,et al.Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2[J].Structure,2013,21(11):1979-1991.
|
[39] |
Goldstein R,Sosabowski J,Livanos M,et al.Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging[J].Eur J Nucl Med Mol Imaging,2015,42(2):288-301.
|
[40] |
田颖.18F标记预设计锚蛋白重复蛋白靶向HER2的PET显像研究[D].广州:南方医科大学,2016.
|
[41] |
Orlova A,Magnusson M,Eriksson TL,et al.Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule[J].Cancer Res,2006,66(8):4339-4348.
|
[42] |
Xu Y,Bai Z,Huang Q,et al.PET of HER2 Expression with a Novel 18FAl Labeled Affibody[J].J Cancer,2017,8(7):1170-1178.
|
[43] |
Heskamp S,Laverman P,Rosik D,et al.Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer[J].J Nucl Med,2012,53(1):146-153.
|
[44] |
Glaser M,Iveson P,Hoppmann S,et al.Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment[J].J Nucl Med,2013,54(11):1981-1988.
|
[45] |
Vu T,Claret FX.Trastuzumab: updated mechanisms of action and resistance in breast cancer[J].Front Oncol,2012,2:62.
|
[46] |
Hudis CA.Trastuzumab--mechanism of action and use in clinical practice[J].N Engl J Med,2007,357(1):39-51.
|
[47] |
Kurokawa Y,Sugimoto N,Miwa H,et al.Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) [J].Br J Cancer,2014,110(5):1163-1168.
|
[48] |
Janjigian YY,Viola-Villegas N,Holland JP,et al.Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET[J].J Nucl Med, 2013,54(6):936-943.
|
[49] |
Gebhart G,Flamen P,De Vries EG,et al.Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2[J].J Nucl Med,2016,57 Suppl 1:81S-88S.
|
[50] |
Holland JP,Caldas-Lopes E,Divilov V,et al.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab[J].PLoS One,2010,5(1):e8859.
|
[51] |
Sijbrandi NJ,Merkul E,Muns JA,et al.A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab[J].Cancer Res,2017,77(2):257-267.
|
[52] |
Dijkers EC,Oude Munnink TH,Kosterink JG,et al.Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer[J].Clin Pharmacol Ther,2010,87(5):586-592.
|
[53] |
O'Donoghue JA,Lewis JS,Pandit-Taskar N,et al.Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer[J].J Nucl Med,2018,59(1):161-166.
|
[54] |
Laforest R,Lapi SE,Oyama R,et al.89ZrTrastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer[J].Mol Imaging Biol,2016,18(6):952-959.
|
[55] |
Franklin MC,Carey KD,Vajdos FF,et al.Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex[J].Cancer Cell,2004,5(4):317-328.
|
[56] |
Yamashita-Kashima Y,Iijima S,Yorozu K,et al.Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models[J].Clin Cancer Res,2011,17(15):5060-5070.
|
[57] |
Ulaner GA,Lyashchenko SK,Riedl C,et al.First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer[J].J Nucl Med,2018,59(6):900-906.
|
[58] |
Zhou Y,Li G,Wu J,et al.Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer[J].Tumour Biol,2010,31(6):549-558.
|
[59] |
Cross MJ,Claesson-Welsh L.FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition[J].Trends Pharmacol Sci,2001,22(4):201-207.
|
[60] |
Jüttner S,Wissmann C,Jons T,et al.Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma[J].J Clin Oncol,2006,24(2):228-240.
|
[61] |
Zhu H,Zhao C,Liu F,et al.Radiolabeling and evaluation of (64)Cu-DOTA-F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer[J].Am J Cancer Res,2015,5(11):3301-3310.
|
[62] |
Friedman HS,Prados MD,Wen PY,et al.Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma[J].J Clin Oncol,2009,27(28):4733-4740.
|
[63] |
van der Bilt AR,Terwisscha van Scheltinga AG,Timmer-Bosscha H,et al.Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model[J].Clin Cancer Res,2012,18(22):6306-6314.
|
[64] |
Jansen MH,Lagerweij T,Sewing AC,et al.Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models[J].Mol Cancer Ther,2016,15(9):2166-7214.
|
[65] |
van Es SC,Brouwers AH,Mahesh SVK,et al.89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma[J].J Nucl Med,2017,58(6):905-910.
|
[66] |
Sharma N,Adjei AA.In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs[J].Ther Adv Med Oncol,2011,3(1 Suppl):S37-S50.
|
[67] |
Comoglio PM,Giordano S,Trusolino L.Drug development of MET inhibitors: targeting oncogene addiction and expedience[J].Nat Rev Drug Discov,2008,7(6):504-516.
|
[68] |
Ishibe S,Karihaloo A,Ma H,et al. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology[J].Development,2009,136(2):337-345.
|
[69] |
Riquelme I,Saavedra K,Espinoza JA,et al.Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy[J].Oncotarget,2015,6(28): 24750-24779.
|
[70] |
Zhang Y,Jain RK,Zhu M.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment[J].Biomedicines,2015,3(1):149-181.
|
[71] |
Price EW,Carnazza KE,Carlin SD,et al.89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection[J].J Nucl Med,2017,58(9):1386-1394.
|
[72] |
Annalisa Petrelli,Paola Circosta,Luisa Granziero,et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity[J]. Proc Natl Acad Sci U S A. 2006 Mar 28; 103(13): 5090-5095. PMCID: PMC1458799
|
[73] |
Merchant M,Ma X,Maun HR,et al.Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent[J].Proc Natl Acad Sci U S A,2013,110(32): E2987-E2996.
|
[74] |
Perk LR,Stigter-van Walsum M,Visser GW,et al.Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30[J].Eur J Nucl Med Mol Imaging,2008,35(10):1857-1867.
|
[75] |
Pool M,Terwisscha van Scheltinga AGT,Kol A,et al.89Zr-Onartuzumab PET imaging of c-MET receptor dynamics[J].Eur J Nucl Med Mol Imaging,2017,44(8):1328-1336.
|
[76] |
Zhang JR,Zhang XY,Chen XT,et al.Purification and partial characterization of a new group of gastric cancer associated antigens[J].Chin Med J (Engl),1991,104(3):212-216.
|
[77] |
Guo DL,Dong M,Wang L,et al.Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori -associated gastric diseases[J]. World J Gastroenterol,2002,8(6):1009-1013.
|
[78] |
Green MA,Mathias CJ,Neumann WL,et al.Potential gallium-68 tracers for imaging the heart with PET: evaluation of four gallium complexes with functionalized tripodal tris(salicylaldimine) ligands[J].J Nucl Med,1993,34(2):228-233.
|
[79] |
Li Z,Zuo XL,Li CQ,et al.In vivo molecular imaging of gastric cancer by targeting MG7 antigen with confocal laser endomicroscopy[J].Endoscopy,2013,45(2):79-85.
|
[80] |
Xu B, Li X, Yin J, et al.Evaluation of 68Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer[J].Scientific Reports,2015,5:8626.
|